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The INK4a/ARF locus encodes the cyclin dependent kinase inhibitor, p16
INK4a and the p53 activator, p14ARF. These two proteins have an independent ®rst exon (exon 1a and exon 1b, respectively) but share exons 2 and 3 and are translated in dierent reading frames. Germline mutations in this locus are associated with melanoma susceptibility in 20 ± 40% of multiple case melanoma families. Although most of these mutations speci®cally inactivate p16 INK4a , more than 40% of the INK4a/ARF alterations located in exon 2, aect both p16
INK4a and p14ARF. We now report a 16 base pair exon 1b germline insertion speci®cally altering p14ARF, but not p16
INK4a
, in an individual with multiple primary melanomas. This mutant p14ARF, 60ins16, was restricted to the cytoplasm, did not stabilize p53 and was unable to arrest the growth of a p53 expressing melanoma cell line. This is the ®rst example of an exon 1b mutation that inactivates p14ARF, and thus implicates a role for this tumour suppressor in melanoma predisposition. Oncogene (2001) (Dracopoli and Fountain, 1996) . In contrast, the CDK inhibitor, p15
INK4b
, does not appear to be important in melanomagenesis, essentially because this gene is frequently retained in melanomas and no germline p15
INK4b mutations have been identi®ed in familial melanoma kindreds (Flores et al., 1997; Platz et al., 1997; Stone et al., 1995) .
Linkage analysis in melanoma prone families (Ruiz et al., 1999) and loss of heterozygosity studies in melanoma tumours (Puig et al., 2000; Ruiz et al., 1998) also suggest the existence of other melanoma genes located in 9p21. The role of p14ARF in melanoma susceptibility remains controversial and has been dicult to resolve because of its unusual genomic structure; p14ARF shares signi®cant coding sequence with p16
INK4a
. The p14ARF and p16
INK4a genes have unique ®rst exons (exon 1b and exon 1a, respectively) but share exons 2 and 3 (Quelle et al., 1995) . As a result, when tumour-associated mutations dually aect p16
INK4a and p14ARF, a situation occurring in approximately 40% of human tumours (Pollock et al., 1996) , the relative contribution of ARF in the genesis of the cancer is not known.
The frequent alteration of both p14ARF and p16
INK4a in tumours is consistent with a model in which the inactivation of the p53 and retinoblastoma cell cycle pathways cooperates in the process of immortalization. p16
INK4a regulates G 1 -phase exit by interacting with CDK4 and CDK6 to inhibit the phosphorylation of the retinoblastoma protein (pRb) (Serrano et al., 1993) . p14ARF regulates both the p53 and pRb pathways, by binding to and inhibiting the function of the proto-oncogene hdm2 (Honda and Yasuda, 1999; Pomerantz et al., 1998; Stott et al., 1998; Weber et al., 1999; Zhang et al., 1998) and targeting the transcription factors, E2F-1, -2 and -3, for degradation (Eymin et al., 2001; Martelli et al., 2001) . Hdm2 promotes the nuclear export and degradation of p53 (Fuchs et al., 1998; Roth et al., 1998) and functionally inactivates pRb. The inactivation of pRb stimulates the activity of the E2F-1 and -3 transcription factors, which are positive regulators of cell cycle progression (Sun et al., 1998; Xiao et al., 1995) . Consequently, the growth inhibitory activity of ARF is suppressed by inactivation of both the pRb and p53 pathways, but remains eective when only one of these pathways has been inactivated (Carnero et al., 2000) . It is not surprising, therefore, that speci®c knock out mice for the murine homologue of p14ARF, p19ARF, are highly tumour prone and their mouse embryo ®bro-blasts are immortal (Kamijo et al., 1997) .
The identi®cation of alterations speci®cally targeting p14ARF, while not altering p16
INK4a or p15
INK4b
, in human tumours has provided evidence that p14ARF is speci®cally targeted during cancer development. The
Oncogene (2001) 20, 5543 ± 5547 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc *Correspondence: H Rizos; E-mail: helen_rizos@wmi.usyd.edu.au or S Puig; E-mail: SPUIG@clinic.ub.es p14ARF-speci®c exon 1b is deleted in the majority of T cell acute lymphoblastic leukemias (Gardie et al., 1998) , and in some astrocytomas and metastatic melanoma cell lines (Kumar et al., 1998; Newcomb et al., 2000) . Mutations in exon 1b have been identi®ed in the HCT116 colon cancer cell line and in a primary colon carcinoma (Burri et al., 2001) . Furthermore, a germline deletion speci®c to exon 1b has been detected in a single kindred predisposed to melanoma and neural system tumours (Randerson-Moor et al., 2001) and a germline missense mutation aecting exon 1b has been recently identi®ed in a French melanoma kindred (Bressac-de Paillerets, personal communication). Although the functional consequence of this mutation is not known, Zhang and Xiong (1999) provided evidence that two cancer-associated missense mutations (p14ARF R98L and p14ARF
R98Q
) impaired the function of p14ARF. We now present an exon 1b mutation identi®ed in a female with multiple primary melanomas. This 16 base pair (bp) insertion does not aect the coding sequence of p16
INK4a but causes a frameshift in p14ARF after codon 21, and inactivates the cell cycle inhibitory function of this tumour suppressor.
The 16 bp insertion (60ins16) in exon 1b of p14ARF was detected in a single individual who developed primary melanomas at 37 and 43 years of age ( Figure  1 ). This Spanish woman did not exhibit dysplastic naevi or a high number of moles, and was identi®ed during an analysis of individuals with multiple primary melanomas, in a study to be reported separately. Subsequent investigation of the family revealed that two of the three proband's daughters (30 and 36 years old) also carry the 60ins16 mutation, but have not developed melanoma or clinically atypical naevi (Figure 1 ). The 60ins16 mutation was not detected in 266 normal chromosomes derived from a group of unrelated control individuals. This alteration places the p14ARF sequence beyond codon 21 in a dierent reading frame and introduces a stop codon at codon 67. The insertion of 16 bp appears to result from a duplication of a CG rich region within exon 1b (Figure  1) , and in this sense is similar to the 24 bp p16 INK4a duplication which has been observed in several melanoma prone kindreds (Walker et al., 1995) . Such duplications are thought to arise during DNA replication, through polymerase slippage or through homologous recombination errors (Pollock et al., 1998) .
The functional analysis of the 60ins16 mutant protein was of interest because this mutant ARF retains the N-terminal nucleolar localization sequence and the hdm2-binding domain of ARF (Figure 1 ). In fact, the amino terminal 15 amino acids of p14ARF are capable of translocating heterologous proteins into the nucleus and nucleolus (Lohrum et al., 2000; Midgley et al., 2000; Rizos et al., 2000; Weber et al., 2000) , stabilizing p53 in vivo and inhibiting the ubiquitination of p53 in vitro (Midgley et al., 2000) . To compare the subcellular distribution of wild type p14ARF and the 60ins16 mutant, the cDNA of each was cloned in frame with the FLAG-epitope in the pFLAG-CMV-5b vector. The subcellular distribution of each construct was evaluated in transiently transfected NM39 melanoma cells. These cells lack endogenous p16
INK4a and p14ARF, but express p53 and pRb (Rizos et al., 1999) . As expected p14ARF-FLAG localized predominantly in the nucleoli of most transfected NM39 melanoma cells (Figure 2 ). In contrast, the p14ARF 60ins16 mutant was retained exclusively in the cytoplasm of almost all transiently transfected NM39 cells (Figure 2 ) and Saos-2 cells (data not shown). Considering that p14ARF 60ins16 retains the N-terminal nucleolar localization sequence, it was surprising that ) sequences are shown. The exon 1b insertion was identi®ed using SSCP analysis and con®rmed by sequencing PCR products in both orientations and sequencing the cloned exon 1b mutant. The 16 bp repeat is highlighted in the mutant sequence and the Nterminal nucleolar localization domain (Rizos et al., 2000) is underlined ectopically expressed p14ARF 60ins16 was retained in the cytoplasm. Only a small proportion of transiently transfected NM39 and Saos-2 cells (2.5% and 6%, respectively) accumulated p14ARF 60ins16 in the cytoplasm and the nucleolus. It is possible that the structure of the chimeric 60ins16 protein masks the ARF-derived nucleolar localization domain resulting in the cytoplasmic sequestration of this mutant.
It is well established that nuclear ARF is required for p53 stabilization and cell cycle inhibition. The p53 stabilizing activity of the p14ARF 60ins16 was evaluated by transiently transfecting NM39 cells with the p14ARF 60ins16 -FLAG or wild type ARF-FLAG construct. Approximately 40 h post transfection cells were immunostained for p53. Of the transfected NM39 cells expressing wild type ARF, 93% accumulated high levels of p53 (Figure 3) . Similarly, 88% of the transfected NM39 cells expressing wild type ARF also accumulated increased levels of the p53 transcriptional target, hdm2 (data not shown). In contrast, only 4% of NM39 cells expressing p14ARF 60ins16 -FLAG accumulated high levels of the p53 protein (Figure 3) and there was no increase in the levels of hdm2 in transfected NM39 cells expressing the 60ins16 variant (data not shown).
The eect of wild type p14ARF or p14ARF 60ins16 on cell cycle progression was investigated by transiently transfecting FLAG-tagged constructs into NM39 melanoma cells. Forty hours after transfection, DNA content was assayed by¯ow cytometry to determine cell cycle distribution. At this time point, the expression of wild type p14ARF in NM39 cells induced potent G1 cell cycle arrest. In contrast, the p14AR-F 60ins16 variant reproducibly failed to arrest transiently transfected NM39 cells (Figure 4) . Consequently, the predominantly cytoplasmic p14ARF 60ins16 mutant is unable to stabilize p53 and fails to induce cell cycle arrest in p53 expressing cells.
The contribution of p14ARF to melanoma development remains unresolved. To date, three alterations speci®c to ARF have been reported in the germline of individuals with melanoma. The functionally impaired Figure 2 Cellular distribution of FLAG-epitope tagged wild type p14ARF and the p14ARF 60ins16 mutant in NM39 melanoma cells. Wild type p14ARF-FLAG was synthesized as previously described (Rizos et al., 2000) . The p14ARF 60ins16 mutant was engineered by PCR-mediated mutagenesis, ligated to the Nterminus of the FLAG-epitope encoded by the pFLAG-CMV-5b vector (Sigma) and completely sequenced. Each p14ARF-FLAGtagged construct was transiently introduced using Lipofectamine 2000 reagent (GIBCO ± BRL), into the NM39 melanoma cells grown on coverslips in 6-well plates. Approximately 40 h post transfection cells were ®xed in 3.7% formaldehyde, permeabilized and immunostained for 50 min with a monoclonal mouse a-FLAG M2 antibody (Sigma) followed by a 50 min exposure to a FITC-conjugated a-mouse IgG antibody (Roche). Nuclei were visualised by Hoechst 33258 staining (2 mg/ml). LM, light microscopy. The proportion of transfected cells showing predominantly nucleolar (Nlo), nuclear and cytoplasmic (N+C) or cytoplasmic only (C) staining is shown in the histograms. Subcellular distribution was determined from two independent experiments. The number (n) of¯uorescent cells counted is indicated -FLAG plasmid were immunostained, 40 h post transfection, for the FLAG and p53 antigens by dual sequential immuno¯uorescence. Proteins were detected with mouse a-FLAG M2 antibody (Sigma) and rabbit a-p53 (Santa Cruz) followed by a 50 min exposure to a FITC-conjugated a-mouse secondary IgG (Roche) and texas redconjugated a-rabbit secondary IgG (Jackson ImmunoResearch). Nuclei were visualized by Hoechst 33258 staining. LM, light microscopy. (b) The proportion of NM39 cells expressing either p14ARF or p14ARF 60ins16 and accumulating increased levels of p53 is expressed as a percentage of all transfected cells. The number (n) of transfected cells counted is indicated p14ARF 60ins16 mutant described in this study, occurs in an individual diagnosed with multiple primary melanomas, but this individual's daughters are also carriers of the mutant ARF gene and are so far unaected at ages under 40 years. A p14ARF
Gly16Asp mutant was recently identi®ed in a French melanoma kindred, but there is no reported functional data on this mutant (Bressac-de Paillerets, personal communication). A germline deletion of the p14ARF-speci®c exon 1b was associated with melanoma-astrocytoma syndrome in a four-case melanoma family (Randerson-Moor et al., 2001) . In addition, approximately 50% of kindreds with melanoma linked to 9p21 do not have detectable alterations in p16
INK4a
. In two such families we found that the allele-speci®c expression of p14ARF from the chromosome segregating with disease was signi®cantly reduced (Rizos et al., 1997) . If we also consider that 40% of melanoma-prone kindreds carry germline alterations that dually aect p16
INK4a and p14ARF, it would appear that the role of p14ARF in melanoma predisposition might have been underestimated. Further studies, including functional analysis of p14ARF mutants and genotype-phenotype correlations are needed to resolve the relative roles of p14ARF and p16
INK4a in melanoma susceptibility and development. . NM39 melanoma cells ( 3610 5 ) were transfected with the indicated p14ARF-FLAG plasmid (3 mg) and pCMVEGFP-spectrin (1 mg). The cell cycle distribution of green uorescent cells was determined, 40 h post transfection, using propidium iodide staining. (a) DNA content from at least 3000 EGFP-spectrin positive cells was analysed using ModFit software. (b) The G 1 -phase arrest induced by wild type p14ARF was set at 100% and the arrest induced by the p14ARF 60ins16 mutant was expressed relative to the wild type protein. Each result is derived from at least three independent transfection experiments
